Comparative Pharmacology
Head-to-head clinical analysis: CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE versus HALCION.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE versus HALCION.
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE vs HALCION
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their synaptic concentrations, while chlordiazepoxide potentiates GABA-A receptor activity, enhancing inhibitory neurotransmission.
Triazolam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and causing neuronal hyperpolarization, leading to CNS depression.
1 capsule (containing chlordiazepoxide 5 mg and amitriptyline HCl 12.5 mg) orally 3-4 times daily; may increase to 2 capsules (10 mg/25 mg) 3-4 times daily if needed.
0.25 mg orally once daily at bedtime, maximum 0.5 mg per day.
None Documented
None Documented
Chlordiazepoxide: terminal half-life 5-30 hours (parent drug), 36-200 hours (active metabolite desmethylchlordiazepoxide); prolonged in elderly and liver disease. Amitriptyline: terminal half-life 13-36 hours (parent), 20-60 hours (active metabolite nortriptyline); dose adjustment needed for hepatic impairment.
Terminal elimination half-life is 1.5–5.5 hours (mean 2.5 hours). Short half-life minimizes next-day sedation.
Chlordiazepoxide: renal excretion of metabolites (60-70% as conjugated metabolites, 1-2% unchanged); fecal excretion ~10%. Amitriptyline: renal excretion of metabolites (30-50% as glucuronides and sulfates, <2% unchanged); biliary/fecal excretion ~20-30%.
Primarily renal (80%) as conjugated metabolites; fecal (8%); unchanged drug <1%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine